

# Yang-Sheng Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1981143/publications.pdf>

Version: 2024-02-01

24  
papers

213  
citations

1163117

8  
h-index

1058476

14  
g-index

25  
all docs

25  
docs citations

25  
times ranked

383  
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis: The effect of patient education on bowel preparation for colonoscopy. <i>Endoscopy International Open</i> , 2015, 03, E646-E652.	1.8	44
2	Systematic review with meta-analysis: risk of postoperative complications associated with preoperative exposure to anti-tumour necrosis factor agents for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 966-977.	3.7	36
3	Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. <i>Nutrition Journal</i> , 2019, 18, 34.	3.4	33
4	Management of <i>Helicobacter pylori</i> infection after gastric surgery. <i>World Journal of Gastroenterology</i> , 2014, 20, 5274.	3.3	27
5	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0233212.	2.5	22
6	Ultrasound Evaluation of Liver Fibrosis. <i>Journal of Medical Ultrasound</i> , 2017, 25, 127-129.	0.4	13
7	Oncologic feasibility for negative pressure wound therapy application in surgical wounds: A meta-analysis. <i>International Wound Journal</i> , 2022, 19, 573-582.	2.9	10
8	Hepatic carcinosarcoma: clinicopathologic features and a review of the literature. <i>Annals of Hepatology</i> , 2013, 12, 495-500.	1.5	8
9	Comparison of telbivudine and entecavir on the change of off-treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients. <i>BMC Gastroenterology</i> , 2017, 17, 22.	2.0	6
10	Factors Affecting the Intraluminal Therapy for <i>Helicobacter pylori</i> Infection. <i>Microorganisms</i> , 2022, 10, 415.	3.6	5
11	<i>Bacillus coagulans</i> (PROBACI) in treating constipation-dominant functional bowel disorders. <i>Medicine (United States)</i> , 2020, 99, e20098.	1.0	4
12	Emphysematous Changes of the Liver. <i>Gastroenterology</i> , 2012, 142, 213-414.	1.3	3
13	Double-Bubble Sign in an Adult Patient. <i>Gastroenterology</i> , 2017, 153, 1191-1192.	1.3	1
14	Efficacy of telbivudine and entecavir against virus reactivation in HBeAg <sup>+</sup> patients undergoing chemotherapy. <i>Medicine (United States)</i> , 2020, 99, e20330.	1.0	1
15	Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease—the jury might still be out. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 465-466.	3.7	0
16	Letter: preoperative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 469-470.	3.7	0
17	Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 970-971.	3.7	0
18	Fidelity of computer-based simulators for fellows training in Taiwan. <i>Advances in Digestive Medicine</i> , 2019, 6, 28-31.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. , 2020, 15, e0233212.		0
20	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. , 2020, 15, e0233212.		0
21	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. , 2020, 15, e0233212.		0
22	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. , 2020, 15, e0233212.		0
23	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. , 2020, 15, e0233212.		0
24	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. , 2020, 15, e0233212.		0